A critical problem in studying ribosome-inactivating proteins (RIPs) lies in the very limited possibility to produce them in heterologous systems. In fact, their inherent toxicity for the producing organism nearly always prevents their recombinant expression. In this study, we designed, expressed and characterized an engineered form of the RIP saporin (SapVSAV), bearing a C-terminal extra sequence that is recognized and bound by the second PDZ domain from murine PTP-BL protein (PDZ2). The coexpression of SapVSAV and PDZ2 in Escherichia coli BL21 cells greatly enhances the production of the toxin in a soluble form. The increase of production was surprisingly not due to protection from bacterial intoxication, but may arise from a stabilization effect of PDZ2 on the toxin molecule during biosynthesis. We found that once purified, SapVSAV is stable but is not toxic to free ribosomes, while it is fully active against human cancer cells. This strategy of co-expression of a toxin moiety and a soluble PDZ domain may represent a new system to increase the production of recombinant toxic proteins and could allow the selection of new extra sequences to target PDZ domains inside specific mammalian cellular domains.
Introduction
Type-I ribosome-inactivating proteins (RIPs) are plant enzymes possessing N-glycosidase activity on a specific adenine residue (A4328 in rat) in the 28S/26S rRNA, thus being able to irreversibly damage eukaryotic and prokaryotic ribosomes Skinner and Jackson, 1998; Hartley et al., 1991; Prestle et al., 1992) . They have been extensively studied in view of their potential applications in the field of targeted anticancer drugs (Fabbrini et al., 2003; Kawakami et al., 2006; Stirpe and Battelli, 2006) . They are typically purified from plant tissues, but in recent years, some of these toxins have been cloned and expressed in bacteria and yeasts (Rajamohan et al., 2000; Lombardi et al., in press ).
The common problem with the production of recombinant type-I RIPs is their inherent toxicity toward the ribosomes of the producing organism. This phenomenon is readily reflected by the slow rate of growth of bacteria upon induction of RIPs (Kataoka et al., 1991; Barthelemy et al., 1993; Fabbrini et al., 1997; Cho et al., 2000; Kwon et al., 2000; Iglesias et al., 2005; Pittaluga et al., 2005) . The main system used for the tight control of the expression of these toxins in Escherichia coli is the T7 RNA polymerase inhibition by the use of pLys E.coli strains producing T7 lysozyme, generally allowing the production of discrete amounts of RIPs (Chaddock et al., 1994) . In some cases, however, following induction, the protein accumulates inside the cell as insoluble fractions from which the full RIP activity is not easy to recover (Rajamohan et al., 1999) . In this respect, there is the need to develop new systems for the protection from selfactivity of the expressed toxin, as we proposed for the production of the ATF-saporin chimera in Xenopus laevis oocytes, through the use of neutralizing anti-saporin antibodies micro-injected together with ATF-saporin mRNA into the cell cytoplasm (Fabbrini et al., 2000) . For the time being, however, no neutralising recombinant anti-saporin antibodies are available for the co-expression with this toxin.
PDZ domains are found in proteins involved in many cellular processes, from the signal transduction to the transport and particularly in synapse formation in mammals (Kurakin et al., 2007) . The first PDZ domains were discovered as sequence repeats in the primary structures of the post-synaptic density 95 (PSD95), disc-large (Dlg) and zona occludens-1 (ZO-1) proteins (Cho et al., 1992) . PDZ domains consist of 80-90 amino acids comprising six beta-strands (betaA to betaF) and two alpha-helices, A and B, compactly arranged into a globular structure. Peptide binding of the ligand takes place in an elongated surface groove as an antiparallel beta-strand interacts with the betaB strand and the B helix . The structure of PDZ domains allows binding to a free carboxylate group at the end of a peptide through a carboxylate-binding loop between the betaA and the betaB strands. They recognize and bind short peptide sequences located at the C-terminus of a protein with K D in the range 1-50 mM (Gianni et al., 2005a) . Recognition of the C-termini represents a 'non-invasive' interaction, very well suited to mediate organization of transport, localization, sorting and spatial arrangement of proteins exposing their individual C-terminal tails that can be recognized and handled by various PDZ domains. Perhaps not surprisingly, many PDZ domain proteins, especially those containing multiple copies of PDZ domains, function as scaffolds at specialized membrane regions in the cell, where they manage to organize and maintain large macromolecular complexes (Kurakin et al., 2007) .
In principle, PDZ domains may be useful for the production of recombinant toxins, if an appropriate recognition sequence can be appended at their C-terminus. Since the C-terminus of RIPs lies in close proximity of the catalytic site, binding of PDZ domain is expected to influence the biological activity of the enzyme (see, for example, the structure of saporin, Savino et al., 2000) . The addition of target signals to the single-chain toxins has already been approached using a KDEL extension appended to the C-terminus of ricin A chain and of saporin (Wales et al., 1992; Vago et al., 2005) . These experiments were aimed at augmenting the cytotoxicity of these proteins against eukaryotic cells, on the basis of the intracellular fate elucidated for the model toxin ricin (Hartley and Lord, 2004; Sandvig and van Deurs, 2005) . Short extra-peptide sequences did not influence the catalytic activity of the two toxins, but induced a substantial increase in ricin A chain cytotoxicity, as expected (Wales et al., 1992) , while saporin did not take any advantage from the KDEL modification (Vago et al., 2005) . This indicates that different intracellular routes are followed by the two toxins once inside the target cells.
In this paper, we describe an engineered derivative of the toxin saporin bearing an extra amino acid sequence (VSAV) at the C-terminus which is the target of the PDZ2 domain from mouse protein tyrosine phosphatase (PTP-BL, Walma et al., 2002) . We demonstrate that the expression of the PDZ2 together with the modified saporin gene in E.coli increases the production of the toxin in BL21 cells. The level of expression is comparable to that obtained in the PlysS protected system. Transient co-expression was achieved by the use of pET28 and pET11 plasmids, but we also obtained a stable co-expression inserting the two genes into a bi-cistronic vector ( pETDuet, Novagen). After induction of this modified toxin, we did not observe a reduction in bacterial growth (which was comparable to untransformed cells), in contrast to what we observed when inducing the wild-type (wt) saporin. After purification from bacterial extract, SapVSAV did not show any toxic activity in an in vitro assay (rabbit reticulocyte lysate) did show cytotoxicity to human U937 and Daudi cells comparable to that of wt saporin. Furthermore, we show that purified saporin-VSAV can bind PDZ2 in vitro, thus indicating that this would also happen in the bacteria. We suggest that the increased expression of SapVSAV in the presence of co-expressed PDZ domain is most likely due to a stabilization of the toxin during its biosynthesis and is not due to protection from saporin cytotoxicity. Thus, this engineered saporin version may represent a new tool for targeted therapies, since it lacks activity if not bound to or absorbed into a eukaryotic cell. Further work is in progress to target different PDZ specific sequences having a role in redirecting the toxin inside a cell to specific organelles by binding to specifically located PDZ-containing proteins (i.e. PIST, a Golgi-associated protein, Hicks and Machamer, 2005) .
Materials and methods

Reagents
All the reagents were from Sigma-Aldrich (St Louis, MA, USA), unless otherwise indicated. All the restriction enzymes, reagents and enzymes for molecular biology were obtained from Fermentas GMBH (St Leon-Rot, Germany).
Bacterial strain and growth conditions
For cloning and expression, DH5a and BL21 (or BL21-pLysS) E.coli strains were used, respectively. BL21-pLysS cells have a T7-lac promoter and a T7-lysozyme protective system included and possess Chloramphenicol resistance (Stratagene).
For the growth curve, transformed bacteria were inoculated into LB broth supplemented with the appropriate selective antibiotic [ampicillin and/or kanamicin (50 mg/ml), chloramphenicol (34 mg/ml)] and cultured overnight at 378C in a New Brunswick incubator. The day after, bacteria were diluted 1:200 into 50 ml of fresh medium and the OD 600 was checked every hour.
For the classical inductions, the overnight culture was always diluted 1:200 in a fresh medium and cultured at 378C.
When the OD 600 value reached 0.4-0.6 protein, expression was induced by adding 1 mM IPTG to 500-1000 ml of culture. Incubation was continued under vigorous shaking at desired temperature (25, 30 or 378C) for 4 h. Finally, the cells were centrifuged at 3000g for 15 min and tested for protein expression.
Vectors pET11d (Amp þ ) (New England Biolabs) containing a saporin gene ( pet-11d-SAP-3) or the pet-11d-SAPKDEL derivative coding for a saporin bearing an extra C-terminal (SEKDEL) and pET28a (Kan þ ) (Novagen) containing PDZ2 were previously obtained in our laboratories (Fabbrini et al., 1997; Gianni et al., 2005b; Vago et al., 2005) . SapVSAV derivative was obtained by site-directed mutagenesis of pet-11d-SAPKDEL vector, as described below. These vectors were used as cloning/expression vector for transient expression, respectively, of SapVSAV and PDZ2 proteins in E.coli BL21 or BL21-pLysS cells.
pETDuet-1 bi-cistronic Vector (Amp þ ) (Novagen), containing both the SapVSAV and the PDZ2 genes, was obtained by subcloning from pET11d-sapSEVSAV and pET28a-PDZ2, as described below, and used for stable expression in E.coli BL21 cells.
Mutagenesis of pet-11d-SAPKDEL and pET28a-PDZ2
The saporin variant with an extra C-terminal SEVSAV sequence (the protein will be referred as SapVSAV throughout this paper) was obtained by replacement of the 3 0 AatI/ StuI-EcoRI cassette already introduced during the construction of the SAPKDEL derivative (Vago et al., 2005) using synthetic oligonucleotides encoding the VSAV sequence. In order to monitor the binding reaction between SapVSAV and PDZ2, all experiments were carried out using a fluorescent pseudo-wt Y43W PDZ2, whose folding and binding reactions were previously extensively characterized (Gianni et al., 2005a .
Subcloning and expression of SapVSAV and PDZ2 genes
The sequence of SapVSAV gene was excised from pET11d with a double digestion (378C, overnight) using NcoI and EcoRI with Tango Buffer 1Â (33 mM Tris-acetate, pH 7.9, 10 mM magnesium acetate, 66 mM potassium acetate, 0.1 mg/ml BSA). After digestion, the enzymes were inactivated at 658C for 20 min.
PDZ2 gene (deriving from pET28a construct) was excised with NdeI in Orange buffer 1Â (50 mM Tris -HCl, pH 7.5,10 mM MgCl 2 , 100 mM NaCl, 0.1 mg/ml BSA). The digestion products were separated from the mix using 1% agarose gel electrophoresis and then excised from gel. The genes were eluted from the gel band using a QIAquick Gel Extraction Kit (Qiagen, USA) and used for ligation with digested pETDuet-1 vector.
Subcloning of two genes (PDZ2 and SapVSAV) was performed in two steps. We first subcloned PDZ2 into the MCS2 of pETDuet-1 vector, due to the possible bi-directional ligation of the gene sequence.
pETDuet-1 vector was digested with NdeI in the same conditions described above, and dephosphorylated using Calf Intestinal Alkaline Phosphatase. Then it was ligated to the purified PDZ2 gene. The ligation assay was performed with gene/vector molar ratio 10:1, with the following times and temperatures: 24 h at 48C, 24 h at 88C, 24 h at 168C and finally 4 h at 218C.
The ligation product was used to transform E.coli DH5a strain according to methods described below. Five colonies growing in a selective LB agar medium (with ampicillin 50 mg/ml) were selected for sequencing of their recombinant construct using the followings primers: DuetUP2 Primer Forward (5 0 TTGTACACGGCCGCATAATC3 0 ) and T7 Terminator Primer Reverse (5 0 CCGCTGAGCAATAACTA GC3 0 ). Two of these colonies showed a correct pETDuet-1 vector with directionally PDZ2 gene insert.
This correct construct pETDuet-1-PDZ2 was used for insertion of the SapVSAV gene. First, it was digested with NcoI and EcoRI with Tango Buffer 1Â (378C, overnight and then inactivated at 658C for 20 min). Doubly digested vector was purified by agarose gel electrophoresis and gel elution of the vector band using a QIAquick Gel Extraction Kit. The purified vector and SapVSAV gene were ligated using gene/ vector molar ratio 10:1, with the following times and temperatures: 24 h at 48C, 24 h at 88C, 24 h at 168C and finally 4 h at 218C.
The ligation products were first used for transformation of E.coli DH5a competent cells following a classical protocol including heat shock and the positive DNA constructs were successively purified from DH5a recombinants to transform BL21 and or BL2-pLysS competent cells (Hanahan, 1983) . All the transformants were plated onto LB agar plates containing appropriate antibiotics and incubated overnight at 378C.
Escherichia coli competent cells and transformation
Competent cells. Escherichia coli (DH5a, BL21 or BL21-pLysS) competent or electrocompetent cells were prepared using standard protocols (Sambrook et al., 1989) .
Cellular fractionation
Induced bacterial pellet 0.3 g was resuspended in Tris -HCl 30 mM, pH 8, EDTA 2 mM and 27% sucrose supplemented with lysozyme (2 mg/ml), and incubated for 1 h at þ48C. The cell suspension was centrifuged at 18 000g for 20 min. The supernatant constitutes the periplasm fraction and the pellet ( protoplast fraction) was further treated in the buffer above described supplemented with dithiothreitol 0.1 mM, proteases inhibitors ( pepstatin 1 mg/ml, leupeptin 1 mg/ml, aprotinin 10 mg/ml, PMSF 15 mg/ml) and DNase 1 mg/ml. This fraction was sonicated on an ice bath and centrifugated at 18 000g for 20 min. The supernatant corresponding to the cytosolic fraction was stored and the pellet of debris was discarded.
SDS-polyacrylamide gel electrophoresis and western blotting
The bacterial lysates were analyzed with SDS -polyacrylamide gel electrophoresis (10% of polyacrilamide) according to the Laemmli (1970) method. The bacterial pellet derived from 1 ml of culture was resuspended in 50 ml of reducing sample buffer (0.5 M Tris -HCl, pH 6.8, 10% glycerol, 4% SDS, 5% b-mercaptoethanol and Bromophenol blue).
The proteins were fixed and stained with silver nitrate method or by Coomassie-staining (Laemmli, 1970) .
For western blotting, the proteins were transferred on PVDF Immobilon-P membranes (Millipore, MA, USA) in Tris -Gly 20 mM pH 8.3 buffer, 0.1% SDS, 20% methanol, using a BioRad blotter (400 mA for 90 min) (Richmond, CA, USA). The saturation of non-specific binding sites was achieved by adding 5% no fatty milk in TBS buffer (TrisHCl 10 mM containing NaCl 9 g/l SDS 0.01%) for 2 h at room temperature and washed five times with TBS. The membrane was then incubated with a rabbit polyclonal antisaporin serum, overnight at room temperature and after washed five times in TBS. The membrane was then treated with a horse anti-rabbit IgG antibody conjugated with horseradish peroxidase (Vector) for 4 h at room temperature. After several washes with TBS, the membrane was revealed by the addition of 3,3-diaminobenzidine (0.6 mM), hydrogen peroxide (4.2 mM) and 4-chloro-1-naphtol (3.6 mM).
Purification of SapVSAV
The pellet of 1 l of culture of induced bacteria [BL21 SapVSAV ( pET11)-PDZ ( pET28)] was resuspended in a 20 mM phosphate buffer pH 6.5 supplemented with proteases inhibitors ( pepstatin 1 mg/ml, leupeptin 1 mg/ml, aprotinin 10 mg/ml, PMSF 15 mg/ml) and DNase 1 mg/ml. The suspension was sonicated and then centrifuged at 7000g for 30 min at þ48C, to eliminate cells debris. The supernatant was acidified at pH 5 with diluted acetic acid, to precipitate contaminant proteins with acidic isoelectric point. This solution was centrifuged at 7500g for 60 min at þ48C. This second supernatant was recovered, neutralized at pH 6.5 and dialyzed for 48-72 h, against 20 mM phosphate buffer pH 6.5 and filtered with 0.22 mM filters before chromatographic separation. The chromatographic purification of saporin was performed by ion-exchange chromatography on Resource S (Amersham Pharmacia) column in 20 mM phosphate buffer pH 6.5 and eluting with a linear NaCl salt gradient (Savino et al., 1998) .
In vitro cell-free protein synthesis inhibition assay
Nuclease-treated reticulocyte lysates (Promega, Madison, WI, USA) were used to translate reporter BMV RNA in the presence or absence of serial logarithmic dilutions of SAPmycHIS6 (from Pichia medium), SapVSAV and recombinant Saporin (from Pichia medium), essentially as described in Fabbrini et al. (1997) , except that in these experiments for radiolabeling incorporation into translated [S]-methionine (Amersham-GE Healthcare, 50-100 ci/mmol) in 12 ml volume at final concentration of 0.75 mci/ml. Percent protein synthesis reported as 100% refers to control samples translated in the absence of toxins. The concentration of toxin inhibiting by 50% translation is the IC 50 and was in the picomolar range as expected for recombinant wt saporin with no C-terminal extension. Description of the constructs, inducible expression and purification of recombinant saporin from Pichia pastoris is presented in Lombardi et al. (in press ).
Protein synthesis inhibition on Daudi and U937 human cells
The ability of each of the recombinant saporin constructs and saporin extracted from the seeds of Saponaria officinalis (SO6) to inhibit protein synthesis in a dose-dependent manner in the human hematological cell lines Daudi (Klein et al, 1975) and U937 (Sundstrom and Nilsson, 1976 ) was evaluated using a 3
[H]-leucine incorporation assay as described previously (Flavell et al., 1991) .
PDZ2 binding to SapVSAV
Equilibrium binding experiments were performed by adding increasing concentrations of SapVSAV to the pre-formed complex between PDZ2 and a dansylated peptide mimicking the physiological ligand for this domain, i.e. D-EQVSAV (Gianni et al., 2005a) . Binding of SapVSAV to PDZ2 was indirectly monitored by measuring the displacement of the peptide, yielding to decreased fluorescence resonance energy transfer (FRET) efficiency between the triptophan residue in position 43 of PDZ2 and the dansyl group on the peptide. Experiments were performed in the presence of 50 mM phosphate buffer pH 7.2 at 258C using a FluoroMax-4 spectroflurometer (Horiba Jobin Yvon).
Results
Transient transfection and expression of SapVSAV in E.coli BL21 cells
We obtained transient transformed E.coli cells by introducing pET11-SapVSAV with pET28-PDZ2 or stably transformed E.coli cells by introducing pet-11d-SAP-3 (for sap wt or pETDuet SapVSAV/PDZ 2 ) by electroporation or chemical permeabilization in either BL21 or BL21 pLysS strain. Cells selected for their resistance to ampicillin and kanamycin were freshly picked and induced during the logarithmic growth phase.
The expression of SapVSAV was tested by western blotting as shown in Fig. 1A : under non-inducing conditions, the SapVSAV protein is not expressed in BL21 cells either at 258C or at 308C (lanes 2 and 3) . In contrast, we observed some expression of SapVSAV in BL21 containing PDZ2, thus suggesting that there is a basal expression of saporin that could be maintained in a stable form in the soluble fraction in the control BL21 strain (lanes 4 and 5). SapVSAV was also expressed at basal levels in pLysS strain but only at 308C. Furthermore, we observed a better expression at 308C rather than at 258C. In a triple transformant strain (BL21 SapVSAV/PDZ2/pLysS), no expression at all was observed.
When IPTG was added, we got comparable expression of SapVSAV under all the conditions tested, except for BL21 cells (Fig. 1B, lanes 2 and 3) , but we noticed a marked reduction of protein aggregates and degradation products when the PDZ2 domain was co-expressed (Fig. 1B, lanes 4 , 5, 9 and 10). Figure 2 reports the fractionation of BL21 SapVSAV/ PDZ2 expressing cells. As clearly shown (Fig. 2B , Coomassie blue staining), the PDZ domain is strongly expressed and is present in all the fractions (see arrow). Consistently with a possible association of SapVSAV with the PDZ domain, we found the toxin in the same fractions, but particularly in the periplasmic one. It is interesting to note that we never observed before the presence of saporin molecules in the periplasmic space of induced bacteria (unpublished results), thus suggesting that this is possibly due to the PDZ2 domain.
Saporin expressed in PDZ2 systems could be easily purified from both periplasmic and cytosolic soluble fractions by ion-exchange chromatography to homogeneity.
Stable transfection and E.coli expression with SapVSAV and PDZ2
As the stability of bacteria bearing plasmids with the same replication origin may be hampered by prolonged duplications, we studied the possibility to insert both PDZ2 and SapVSAV inside a single plasmid. We found the Novagen vector pETDuet appropriate, having two multi-cloning sites available that could host the two gene sequences. We performed a subcloning procedure to insert SapVSAV inside the upstream (starting from the T7 promoter) and PDZ2 inside the downstream site. The correct insertion of the two genes was verified by DNA sequencing.
The expression of SapVSAV under non-inducing and inducing conditions is reported in Fig. 3 . As shown, the expression of PDZ2 domain is reduced if compared with pET28-based expression in BL21 cells. Notwithstanding this phenomenon, we also observed the expression of SapVSAV both at 308C and at 258C (lanes 7 and 9), with an increase at 258C. We also observed a clear expression of the toxin at 258C (lane 6) even in the absence of induction, as also reported in BL21 cells bearing pET11-SapVSAV and pET28-PDZ2.
Growth curves of saporinVSAV-containing E.coli strains Figure 4 shows the growth curves of BL21 E.coli transfected with pet-11d-SAP-3, pET11-pET11SapVSAV and pETDuetSapVSAV-PDZ2. As clearly shown, under noninducing conditions at 308C, we got similar growth for all strains. Upon induction with IPTG, however, sap wt expression shows a clear cytotoxic effect on the bacterial growth, while SapVSAV is instead devoid of any detectable toxicity. The co-expression in the pETDuet system showed a delay in the onset of the log phase, as already observed for all the BL21 strains containing the PDZ2 gene (data not shown).
Interaction of SapVSAV with PDZ2 domain in vitro
We measured the binding of saporinVSAV and the PDZ2 domain in vitro by looking at the displacement from PDZ2 of a previously characterized synthetic peptide, mimicking the physiological ligand of this peptide domain (D-EQVASAV) (Gianni et al., 2005a) . This peptide contains a dansyl group at the N-terminus that allows to monitor binding by measuring FRET between a fluorescence donor (Trp 43 in PDZ2) and an acceptor (danysl). When saporin binds PDZ2, the peptide is displaced and the FRET signal is decreased. As clearly shown in Fig. 5 , the analysis of equilibrium fluorescence spectra, using increasing concentrations of SapVSAV to displace the peptide, clearly demonstrates that PDZ2 is capable of binding saporinVSAV in vitro. The apparent equilibrium dissociation constant calculated from the data is 19 mM, consistent with what measured before for the binding of the peptide to PDZ2 in solution (Gianni et al., 2005a) .
Biological properties of SapVSAV
We tested the activity of the purified SapVSAV in a cell-free system, using a rabbit reticulocyte lysate system to measure protein synthesis inhibition. As shown in Fig. 6 , the activity of SapVSAV (IC 50 ! 10 28 M) is greatly reduced if compared with that of wt saporin (IC 50 ¼ 2 Â 10 211 M), and comparable to another inactive mutant generated in our lab (i.e. a saporin molecule with a carboxy-terminal C-myc tag and a 6-His sequence).
When the same proteins were tested on a whole cellular system, constituted of human U937 and Daudi cells (the first being a monocytic and the second being a lymphocytic cell line), surprisingly we measured a completely restored catalytic activity (Fig. 7A and B) . The IC 50 values measured are Engineering a switchable toxin comparable to that of wt saporin. In the same experiments, the C-myc-His6 saporin derivative still is lacking biological activity, demonstrating that the effect observed on the cellfree system was not an artifact and that SapVSAV becomes cytotoxic following an activation step taking place at the cell surface or inside the cell. 
Discussion
The production of recombinant ribosome damaging enzymes (i.e. RIPs) has always presented complications, due to the high sensitivity of the host organism to the catalytic activity of the toxin (Habuka et al., 1990; Prestle et al., 1992; Skinner and Jackson, 1998; Rajamohan et al., 1999; Nagasawa et al., 2008) . In an attempt to overcome this we decided to engineer a single-chain RIP (saporin, from the plant S. officinalis), adding a recognition sequence at the carboxy-terminus. The tetrapeptide VSAV added at the terminal portion of saporin (thus giving SapVSAV) has already been recognized as a target sequence for the binding of the PDZ2 domain from the PTB-BL protein (Gianni et al., 2005b) . Furthermore, it has been shown that RIPs interact via their C-terminal domain with other proteins such as ribosomal stalk proteins (McCluskey et al., 2008) .
Our design was based on the hypothesis that if the two proteins were co-expressed within the same host, a potential inhibition of saporin toxicity could be achieved because the carboxy-terminus of saporin is located just in front of the catalytic site cleft. Moreover, since the binding of PDZ2 is expected to create the steric hindrance necessary for inhibition, the catalytic activity of this engineered toxin should be triggered by removal of PDZ2.
We obtained transient co-expression of PDZ2 and SapVSAV in E.coli BL21 and compared the expression of the toxin either with the one obtained in unprotected bacterial cells or in the more stringent expression system (E.coli pLysS strain). We found that SapVSAV could be expressed at good levels at 308C in co-expression with PDZ2, with yields comparable to the classical protected system pLysS. Furthermore, we observed a marked increase in SapVSAV in the presence of PDZ2 also under basal conditions (no IPTG added) as well as a reduction in aggregates, following induction. In contrast, we could not detect any expression in E.coli in the absence of PDZ2. Furthermore, we demonstrated that SapVSAV is found in the same subcellular fractions of PDZ2, being present both in the soluble cytosolic fraction and in the periplasmic space. PDZ2 under the conditions tested in highly overexpressed, and it also accumulates in the periplasmic space, where it is possibly able to transport SapVSAV upon binding to the VSAV sequence at the carboxy-terminus. The binding of PDZ2 to SapVSAV has been demonstrated by in vitro experiments using the purified toxin bearing VSAV sequence, to displace a synthetic peptide bound to the PDZ2 domain via the same tetrapeptide. The estimated K D for this interaction is comparable to what has been previously observed using an unlabeled peptide as a competitor (Gianni et al., 2005a) . Thus, we are confident that the interaction between SapVSAV and PDZ2 occurs also in vivo and therefore E.coli BL21 strain is a suitable host for the recombinant SapVSAV expression. Furthermore, since it is known from the literature that two plasmids bearing the same origin of replication can compete in a single host, thus hampering the stability of the strain upon prolonged replications, we also produced a bi-cistronic plasmid ( pETDuetbased) expressing both the proteins obtained and again similar results as with the single plasmids co-transformation.
Surprisingly, when we tested the biological activity of SapVSAV on a cell-free system, we did not observe protein synthesis inhibition. These results are consistent with the lack of an effect of SapVSAV expression on bacterial cell growth, where induction of expression does not reduce bacterial growth, as it occurs in the case of expression of wt saporin (Fabbrini et al., 1997; Pittaluga et al., 2005) . SapVSAV is produced in bacteria apparently in an inactive form.
The increase of expression of SapVSAV in bacteria upon co-expression of PDZ2 may therefore induce a stabilization of the mutant protein and a reduction of its intracellular degradation. Even more surprisingly, when we tested SapVSAV in cellular systems (Daudi or U937 cells), we observed a cytotoxic activity for SapVSAV comparable to that of wt saporin, suggesting a possible activation mechanism induced in mammalian cells. It is also worth noting that saporin can induce cellular apoptosis possibly targeting substrates other than ribosomes (Polito et al., 2009) .
Saporin is a well-studied toxin that has been used for the production of chimeric immunotoxins (Flavell, 1998; Flavell and Flavell, 2001; Fabbrini et al., 2003; Lombardi et al., in press ) and so far is one of the most useful tools in the neurobiology research (Lappi and Wiley, 2004) . A protective Engineering a switchable toxin system for the production of recombinant saporin chimeras has already been demonstrated (Fabbrini et al., 2000) , but this is not a large-scale production method, since it makes use of intracellular immunization of Xenopus oocytes microinjected with neutralizing anti-saporin antibodies. Our results demonstrate that it is possible to promote the interaction of saporin variant molecules with PDZ domains within a bacterial host, but our data suggests that this interaction is not a protective system but rather the SapVSAV protein was, in this case, protected from aggregation and degradation inside the bacterial host while the protein can be activated in mammalian cells by an as yet unidentified mechanism. Engineering the toxin with other PDZ-specific sequences may also allow us to target the toxin to specific mammalian intracellular compartments, where PDZ-carrying proteins may recruit saporin to specific membranes and possibly increase its toxicity for the cell. Further experiments are ongoing to demonstrate a possible protease cancer-specific activation of SapVSAV, which could represent for this modified toxin an attractive tool for cancer therapy.
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